Skip to main content
. Author manuscript; available in PMC: 2008 Jul 1.
Published in final edited form as: Brain Behav Immun. 2006 Oct 31;21(5):569–580. doi: 10.1016/j.bbi.2006.09.001

Figure 6.

Figure 6

BRL44408 reversal of clonidine’s effect in apoptotic cells, lymphocytes, TGF-β1 (TGF), anti-inflammatory macrophages and Th-1 type lymphocytes in sciatic nerve 24 hr after treatments. Normalized data of zymosan plus clonidine (z+c) and zymosan plus BRL44408 and clonidine (z+BR+c). A. BRL44408 reversal of clonidine’s effect in caspase-3, ED1 and TGF-β1 immunostaining. B. BRL44408 reversal of clonidine’s effect in apoptotic lymphocytes analyzed as number of CD2 and caspase-3 co-localization immunostaining and proportion of caspase-3 co-expression in the CD2 set. C. BRL44408 reversal of clonidine’s effect in anti-inflammatory macrophages analyzed as number of ED1 and TGF-β1 co-localization immunostaining and proportion of TGF-β1 co-expression in the ED1 set. D. BRL44408 reversal of clonidine’s effect in pro-inflammatory Th-1 type lymphocytes analyzed as number of CD2 and caspase-3 co-localization immunostaining and proportion of STAT 4co-expression in the CD2 set. *P<0.05 comparison vs. zymosan plus clonidine group.